title: Development and present state of hormone replacement therapy.
abstract: The first therapeutic trials to evaluate the treatment of climacteric symptoms by the administration of ovarian tissue were reported in 1896, i.e. before the endocrine function of the ovary was known or estrogens had been discovered. These were followed by investigations using various ovarian, placental and urine extracts, implantation of ovarian tissue and by oral treatment with dried ovarian tissue. However, reasonably acceptable hormonal drugs did not become available until the third decade of this century, while drugs meeting modern requirements, including that of oral activity, have been available only since the 1940s. It took at least 20 more years before publications for lay people and intensive endocrinological research convinced both the affected women and the medical profession of the value and even the necessity of hormonal treatment for ovarian-deficiency sequelae. Nowadays the treatment of climacteric and post-climacteric symptoms with estrogens and progestogens is a highly effective and indeed common practice. However, their use is of less value for the therapy of post-climacteric cardiovascular diseases and osteoporosis. As regards the latter, it may be said that androgenic-anabolic steroids and Org OD 14, a steroid related to norethynodrel, have usefully extended the available therapeutic armamentarium. Estrogens and progestogens are widely used for the prophylaxis of post-climacteric osteoporosis and cardiovascular diseases because their exceptional efficacy is well proven. Intensive research has resulted in the development of highly effective and virtually harmless hormonal drugs that are available in a great variety of formulations for all possible modes of administration.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: International Health Foundation, Brussels, Belgium.
authors.forename: H
authors.initials: H
authors.lastname: Kopera
authors.forename: P A
authors.initials: PA
authors.lastname: van Keep
mesh_terms: D045930:Anabolic Agents / Q000627:therapeutic use; D000728:Androgens / Q000627:therapeutic use; D002979:Climacteric / Q000187:drug effects; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D005260:Female; D006801:Humans; D008593:Menopause / Q000187:drug effects; D009652:Norpregnenes / Q000627:therapeutic use; D011372:Progestins / Q000627:therapeutic use
chemical_list: D045930:Anabolic Agents; D000728:Androgens; D009652:Norpregnenes; D011372:Progestins; C027385:tibolone